Showing 4081-4090 of 6590 results for "".
- Sun Pharma Introduces Leave Acne Behind Patient Initiativehttps://practicaldermatology.com/news/sun-pharma-introduces-leave-acne-behind-patient-initiative/2458310/Sun Pharma introudced a new initiative— “Leave Acne Behind™" — to educate patients and create awareness of severe recalcitrant nodular acne (SRNA). Sun Pharma reports that out of all of the prescription- treated acne cases today, 20 percent represent severe acne condi
- First Patient Treated in Dermata Therapeutics Phase 2 Acne Rosacea Clinical Studyhttps://practicaldermatology.com/news/first-patient-treated-in-dermata-therapeutics-phase-2-acne-rosacea-clinical-study/2458316/The first patient has been dosed in Dermata Therapeutics’s Phase 2 acne rosacea study of DMT210, a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne ro
- Skin Cancer Foundation: Bill Ridenour Is New Senior Director of Partnership Developmenthttps://practicaldermatology.com/news/skin-cancer-foundation/2458333/The Skin Cancer Foundation has appointmented Bill Ridenour to the role of senior director of partnership development. Ridenour’s career has spanned over 30 years in the advertising industry and this new position marks a switch to the nonprofit sector. Prior to his appointment, Ridenour
- EZDERM Partners With Healthmonix to Provide Integrated MIPS Reporting for Dermatologistshttps://practicaldermatology.com/news/ezderm-partners-with-healthmonix-to-provide-integrated-mips-reporting-for-dermatologists/2458337/EZDERM, LLC and Healthmonix have partnered to integrate the MIPSPRO platform into the EZDERM suite of dermatology software solutions, including the integrated EZDERM Electronic Health Record and Practice Management systems. This partnership gives EZDERM clients access to education,
- Study: Partner-Assisted Skin Self-Exams for Melanoma Don't Cause Embarrassmenthttps://practicaldermatology.com/news/study-partner-assisted-skin-self-exams-for-melanoma-dont-cause-embarrassment/2458345/Patients with melanoma may benefit from having their partners help to examine their skin for new skin cancers, and this does not cause embarrassment or discomfort for the patient or partner, finds a new study in
- Patient Enrollment Complete in Phase 3 Acne Trials for Minocycline Foam FMX101https://practicaldermatology.com/news/patient-enrollment-complete-in-phase-3-acne-trials-for-minocycline-foam-fmx101/2458357/Patient enrollment is now complete for two Phase 3 clinical trials evaluating the efficacy and safety of FMX101, a topical 4 percent minocycline foam for the treatment of moderate-to-severe acne, according to Foamix Pharmaceuticals Ltd. Foamix is con
- Consumer Reports IDs Teaching Hospitals That Expose Patients to Central Line Infectionshttps://practicaldermatology.com/news/consumer-reports-ids-teaching-hospitals-that-expose-patients-to-central-line-infections/2458366/Too many teaching hospitals are still exposing patients to dangerous bacteria via central line infections, according to Consumer Reports. The new report identifies
- Precision Medicine in Action: Clinical Features May Help ID High Risk Melanoma Patientshttps://practicaldermatology.com/news/precision-medicine-in-action-clinical-featires-may-help-id-high-risk-melanoma-patients/2458379/Zeroing in on an individual’s risk factors for melanoma can help identify high-risk patients who may benefit from increased surveillance, new research suggests. Caroline G. Watts, M.P.H., of the University of Sydney, Australia, and coauthors examined clinical features associated wit
- NPF Offers Open Enrollment Insurance Advice Via New Patient Navigation Centerhttps://practicaldermatology.com/news/national-psoriasis-foundation-offers-open-enrollment-insurance-advice-via-new-patient-navigation-center/2458380/The National Psoriasis Foundation (NPF) Patient Navigation Center aims to help patients l
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to inves